Neumora Therapeutics, Inc. (NMRA) Stock Price & Analysis
Neumora Therapeutics, Inc. (NMRA) rose 1.85% to USD 1.65 as of June 10, 2026 at 11:48 UTC, according to Nexqual real-time market data.
NMRA last closed at USD 1.62; the session ranged USD 1.61–1.7 on volume of 785,181 shares. Market capitalization is $305.72M, with a 52-week range of USD 0.72–3.65 (NMS). Source: Nexqual, June 10, 2026 at 11:48 UTC.
Key Statistics (as of June 10, 2026 at 11:48 UTC)
| Price | USD 1.65 |
|---|---|
| Change | ▲ 1.85% (up) |
| Previous Close | USD 1.62 |
| Open | USD 1.65 |
| Day Range | USD 1.61 – 1.7 |
| 52-Week Range | USD 0.72 – 3.65 |
| Volume | 785,181 shares |
| Market Cap | $305.72M |
| Exchange | NMS |
Technical Analysis (NMRA)
Nexqual's technical model rates NMRA "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 11:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.62 (neutral) |
| vs SMA50 | Below (USD 2.02) |
| MACD | -0.11 (negative) |
Analyst Ratings (NMRA)
Wall Street analysts rate NMRA "Buy" based on 8 analysts, with a mean price target of USD 8.91 (range USD 3–18), per Nexqual as of June 10, 2026 at 11:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 8.91 |
| High Target | USD 18 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 7 / 1 / 1 |
Earnings (NMRA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.24 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.3 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.35 vs est -0.33 ▼ miss |
| 2025-09-30 | USD -0.35 vs est -0.34 ▼ miss |
| 2025-06-30 | USD -0.33 vs est -0.37 ▲ beat |
Source: Nexqual, June 10, 2026 at 11:48 UTC.
Financials & Fundamentals (NMRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 52.96 |
Source: Nexqual, June 10, 2026 at 11:48 UTC.
Financial Health Score (NMRA)
Nexqual rates Neumora Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 11:48 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — Debt/Equity 0.5x |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (NMRA)
| Insider Ownership | +23.60% |
|---|---|
| Institutional Ownership | +57.91% |
| Shares Outstanding | 185.28M |
| Float | 104.83M |
| Short % of Float | +5.20% |
Source: Nexqual, June 10, 2026 at 11:48 UTC.
Leadership (NMRA)
Neumora Therapeutics, Inc. is led by Joshua Pinto (age 40), President, per Nexqual as of June 10, 2026 at 11:48 UTC.
| President | Joshua Pinto (age 40) |
|---|---|
| CFO & Principal Accounting Officer | Michael Lee Milligan (age 52) |
| Chief Scientific Officer | Nicholas Brandon (age 50) |
| Senior Vice President of Clinical Development | Paul Yeung M.D., M.P.H. |
Major Backers & Investors (NMRA)
Notable institutional backers of Neumora Therapeutics, Inc. include Siren, L.L.C., Softbank Group Corporation, Perceptive Advisors Llc, according to Nexqual as of June 10, 2026 at 11:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Siren, L.L.C. | 4.59% |
| Softbank Group Corporation | 3.29% |
| Perceptive Advisors Llc | 2.75% |
| MIC Capital Management UK LLP | 2.41% |
| FMR, LLC | 1.89% |
| Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust | 1.79% |
| Millennium Management | 1.49% |
| ICONIQ Capital, LLC | 1.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.24% |
Source: Nexqual, June 10, 2026 at 11:48 UTC.
From Neumora Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
- The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
- It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders.
- In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | USD 85 | ▼ 2.21% |
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| CGON | CG Oncology, Inc. | USD 56.67 | ▲ 5.49% |
| ANRO | Alto Neuroscience, Inc. | USD 21.15 | ▲ 15.83% |
| LXEO | Lexeo Therapeutics, Inc. | USD 4.24 | ▼ 2.97% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:48 UTC. This page is informational and not investment advice.